Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies by Maciocia, Paul M. et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/106779/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Maciocia, Paul M, Wawrzyniecka, Patrycja A, Philip, Brian, Ricciardelli, Ida, Akarca, Ayse U,
Onuoha, Shimobi C, Legut, Mateusz, Cole, David, Sewell, Andrew, Gritti, Giuseppe, Somja, Joan,
Piris, Miguel A, Peggs, Karl S, Linch, David C, Marafioti, Teresa and Pule, Martin A 2017.
Targeting the T cell receptor -chain constant region for immunotherapy of T cell malignancies.β
Nature Medicine 23 (12) , pp. 1416-1423. 10.1038/nm.4444 file 
Publishers page: http://dx.doi.org/10.1038/nm.4444 <http://dx.doi.org/10.1038/nm.4444>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Maciocia	et	al	 Targeting	differences	in	TCR-Β	 Page	1	of	35	
		
	 1	
 1	
 2	
TITLE 3	
Targeting T-cell receptor β-constant for immunotherapy of T-cell malignancies   4	
 5	
 6	
AUTHORS 7	
Paul M. Maciocia1, Patrycja A. Wawrzyniecka1, Brian Philip1, Ida Ricciardelli2, Ayse U. 8	
Akarca1, Shimobi Onuoha3, Mateusz Legut4, David K. Cole4, Andrew K. Sewell4, 9	
Giuseppe Gritti5, Joan Somja6, Miguel A. Piris7, Karl S. Peggs1, David C. Linch1, Teresa 10	
Marafioti1, Martin A. Pule1,3* 11	
 12	
1 University College London, Cancer Institute, London, UK 13	
2 University College London, Institute of Child Health, London, UK 14	
3 Autolus Ltd, London, UK 15	
4 Division of Infection and Immunity, Cardiff University School of Medicine, UK 16	
5 Department of Haematology, Papa Giovanni XXII Hospital, Milan, Italy 17	
6 Department of Anatomy and Cellular Pathology, University of Liege, Belgium 18	
7 Anatomical Pathology Service, University Hospital Marques de Valdecilla (IFIMAV), 19	
Santander, Spain 20	
 21	
* Corresponding author 22	
 23	
ACKNOWLEDGEMENTS 24	
PM was supported by a studentship from Cancer Research UK. M. Pule and TM are 25	
supported by the UK National Institute of Health Research University College London 26	
Hospital Biomedical Research Centre. AA and ML are supported by Cancer Research 27	
UK. DKC is a Wellcome Trust Career Development Fellow. AKS is a Wellcome Trust 28	
Senior investigator. This project is supported by grants from the Kay Kendall 29	
Leukaemia Fund and Innovate UK. We would like to thank Dr Michael Owen and Dr 30	
Joanne Viney for helpful discussions. 31	
 32	
 33	
 34	
 35	
CONTRIBUTIONS 36	
Maciocia	et	al	 Targeting	differences	in	TCR-Β	 Page	2	of	35	
		
	 2	
PM designed and performed the experimental work and wrote the manuscript. PW 37	
performed experimental work. BP designed and performed in vivo experiments, and 38	
wrote the manuscript. IR generated and tested EBV-CTLs. AA performed 39	
immunohistochemistry. SO, DC and AS produced soluble TCR molecules, performed 40	
surface plasmon resonance analysis and wrote the manuscript. ML and AK identified 41	
and characterised iNKTs. GG, JS and M.Piris supplied clinical samples. KP and DL 42	
helped design experiments and wrote the manuscript. TM optimised and analysed 43	
immunohistochemical staining, and wrote the manuscript. M.Pule conceived the idea, 44	
designed the experimental work and wrote the manuscript. 45	
 46	
 47	
  48	
Maciocia	et	al	 Targeting	differences	in	TCR-Β	 Page	3	of	35	
		
	 3	
ABSTRACT 49	
 50	
Mature T-cell cancers are typically aggressive, treatment-resistant and associated with 51	
poor prognosis. Translation of immunotherapeutic approaches has been limited by a 52	
lack of target antigens discriminating malignant from healthy T-cells. Unlike B-cell 53	
depletion, pan T-cell aplasia is prohibitively toxic. We report a novel targeting strategy 54	
based on the mutually exclusive expression of either TRBC1 or TRBC2 T-cell receptor 55	
(TCR) b-constant domain. We identify an antibody with unique TRBC1 specificity, and 56	
use this to rapidly screen for T-cell clonality, demonstrating that while normal and viral-57	
specific T-cells contain TRBC1 and TRBC2 compartments, malignancies are restricted 58	
to only one. As proof of concept for anti-TRBC immunotherapy, we developed anti-59	
TRBC1 CART-cells, which recognise and kill normal and malignant TRBC1 but not 60	
TRBC2 T-cells, in vitro and in a disseminated murine leukaemia model. Unlike non-61	
selective approaches targeting the entire T-cell population, TRBC-targeted 62	
immunotherapy could eradicate a T-cell malignancy while preserving sufficient normal 63	
T-cells to maintain cellular immunity.  64	
 65	
 66	
 67	
  68	
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INTRODUCTION 69	
 70	
Mature T-cell lymphomas (PTCLs) are a heterogeneous group of disorders, 71	
collectively comprising 10-15% of non-Hodgkin’s lymphoma1. These cancers typically 72	
behave aggressively2,3. Outcomes are worse than equivalent B-cell cancers, with an 73	
overall estimated 5-year survival of only 32%3. Furthermore, while treatment of B-cell 74	
cancers benefits from targeted immunotherapies such as therapeutic monoclonal 75	
antibodies (mAbs)4, bispecific T-cell engagers5 and more recently chimeric antigen 76	
receptor (CAR) T-cell therapy6,7, no such approaches are available for T-cell cancers. 77	
 78	
Immunotherapies used in B-cell malignancies target pan B-cell antigens, since no 79	
antigens exist which discriminate normal from malignant B-cells. The consequent 80	
depletion of the normal B-cell compartment is surprisingly well tolerated and is 81	
considered an acceptable side-effect6,7. The situation is different with T-cells: once 82	
again, no antigens exist which discriminate normal from malignant T-cells3,8; however, 83	
T-cell aplasia consequent to targeting a pan T-cell antigen would lead to profound and 84	
unacceptable immunosuppression9. Here, we describe a targeting approach for 85	
treating mature T-cell cancers which relies on recognition of a pan T-cell antigen, but 86	
avoid severe immunosuppression. 87	
 88	
The α/β T-cell receptor (TCR) is a pan T-cell antigen. Apart from its expression on 89	
normal T-cells it is an ideal target: it is expressed by >95% of cases of PTCL-NOS8, 90	
almost all AITL8, as well as 30% of T-acute lymphoblastic leukaemia (T-ALL)10. High 91	
and homogenous surface expression is commonly seen on lymphoma cells11 and in 92	
addition, evidence exists that a proportion of PTCL cases may depend on TCR-93	
associated signalling for lymphomagenesis and survival12. TCR α and β chains 94	
comprise amino-terminal variable and carboxy-terminal constant regions13 (Figure 1a). 95	
TCR diversity is generated by somatic recombination, when each TCR chain selects a 96	
variable (V), diversity (D), joining (J) and constant (C) region13. Importantly, cells of a 97	
clonal T-cell population all express the same unique TCR. However, approaches 98	
targeting TCR variable regions unique to a malignant clone are impracticable, since a 99	
bespoke therapeutic is required for each patient. 100	
 101	
An oft-forgotten feature of TCR β-chain recombination is that there are two β-constant 102	
region genes: TRBC1 and TRBC2. Each TCR (and therefore each T-cell) expresses, 103	
mutually exclusively and irreversibly, TCR b-constant coded by either TRBC1 or 104	
TRBC214,15 (Figure 1b).  Hence, normal T-cells will be a mixture of individual cells 105	
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expressing either TRBC1 or 2, while a T-cell cancer will express either TRBC1 or 2 in 106	
its entirety. We propose targeting TRBC1 in case of a TRBC1+ T-cell malignancy, or 107	
the converse in case of a TRBC2+ malignancy. This will target all cells of the malignant 108	
clone, but leave a substantial proportion of the T-cell compartment intact. 109	
 110	
In this work, we demonstrate that it is possible to distinguish between TRBC1 and 2 111	
TCRs with an antibody, despite almost identical amino acid sequences (Figure 1c). 112	
We show that peripheral blood T-cells in normal subjects comprise of a mixture of 113	
approximately 35:65% TRBC1/2 cells, and that complete depletion of either TRBC1 or 114	
2 compartments will still maintain adequate viral immunity. We confirm TRBC clonality 115	
in many types of T-cell malignancies by both flow cytometry and 116	
immunohistochemistry. Finally, we demonstrate efficacy of a CAR with TRBC1 117	
specificity to prove our targeting concept. 118	
 119	
  120	
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RESULTS 121	
 122	
JOVI-1 mAb is specific for TRBC1-expressing cells 123	
 124	
To find a TRBC specific binder, we screened anti-TCR mAbs which are known to bind 125	
a proportion of T-cells in peripheral blood. In order to screen for TRBC1/2 specificity 126	
we cloned the α and β-chains of the well-characterised HA-1 TCR16 in TRBC2 (native) 127	
format or with mutations introduced in the constant domain to convert to TRBC1.  We 128	
stably expressed either TCR on the surface of Jurkat T-cell line with knocked out TCR 129	
α and β loci (JKO). Analysis by flow cytometry demonstrated that, while both TRBC1-130	
JKO and TRBC2-JKO lines expressed surface TCR/CD3, mAb JOVI-117 recognised 131	
only TRBC1-JKO cells and not TRBC2-JKO cells (Figure 1d), confirming the TRBC1 132	
specificity of this antibody. Surface plasmon resonance analysis demonstrated that 133	
JOVI-1 bound to a TRBC1-TCR with an affinity of KD = 0.42nM and a half-life of 134	
~30mins, in line with other therapeutic antibodies18.  In contrast, JOVI-1 binding to a 135	
TRBC2-TCR was >10,000x weaker, demonstrating the remarkable specificity of the 136	
reagent (supplementary Figure 1).  137	
 138	
TCR β-junctional regions segregate with constant domains: TCRs selecting TRBJ1 1-139	
6 use TRBC1, and those selecting TRBJ2 1-7 use TRBC213.  It was therefore possible 140	
that JOVI-1 only maintains TRBC1-specificity in the context of particular junctional 141	
regions.  We cloned several TCRs of varying antigen specificity, utilising a range of 142	
variable/ junctional regions, from publicly available sequences.  When transfected into 143	
human embryonic kidney (HEK)-293T cells along with a plasmid supplying the 144	
components of CD3, TCRs were expressed on the cell surface. JOVI-1 uniformly 145	
recognised TRBC1 cells despite varying TRBJ1 regions, and did not recognise cells 146	
expressing TRBC2 TCRs and varying TRBJ2 regions (Figure 1e). In addition, we 147	
cloned a truncated TCR lacking α and β V(D)J domains. CD3 staining confirmed 148	
surface assembly, and staining with JOVI-1 was similar to that seen with full-length 149	
TCR (Figure 1f). This offered further confirmation that junctional regions were not 150	
required for the JOVI-1 epitope. 151	
 152	
We then sought to determine the residues of TRBC responsible for the TRBC1-153	
specificity of JOVI-1. Structural analysis suggested that the F->Y at residue 36 is 154	
buried in secondary structure and V->E at residue 135 is likely too close to the 155	
membrane to be accessible. However, the NK->KN difference at residues 4-5 is 156	
exposed to the surface and represents a substantial difference of both shape and 157	
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charge to the epitope. By introducing each mutation required to convert TRBC2 to 158	
TRBC1 individually, we confirmed that the reversal of asparagine and lysine residues 159	
at positions 3-4 was indeed the discriminating portion of the JOVI-1 epitope (Figure 160	
1f,g).  161	
 162	
 163	
Normal αβ T-cells contain a mixture of TRBC1+ and TRBC1- populations 164	
 165	
Using JOVI-1, we then sought to determine the proportion of T-cells from normal 166	
donors that were TRBC1 versus TRBC2. Each donor had TCR+TRBC1+ and 167	
TCR+TRBC1- cells in both CD4 and CD8 compartments, with median TRBC1 168	
expression of 35% (range 25-47%, Figure 2a,b). We also confirmed that CD4 and CD8 169	
differentiation subsets all contained both populations with a similar TRBC1:TRBC2 170	
ratio (Suppl Fig 2a,d).  In addition, we identified 2 cell types which express a semi-171	
invariant restricted TCR repertoire, mucosal-associated invariant T-cells (MAITs, suppl 172	
Fig 2b,d) and invariant natural killer/ T-cells (iNKTs, suppl Fig 2c,d)  and demonstrated 173	
that these populations also contain both TRBC1+ and TRBC1- cells, albeit with a lower 174	
TRBC1 proportion than seen in bulk T-cell populations. 175	
 176	
 177	
Although the polyclonal T-cell population in normal donors contained both TRBC1 and 178	
TRBC2 cells, we reasoned that the T-cell response to a particular virus may be skewed 179	
towards one of these, and therefore that removal of one subset could result in loss of 180	
cellular immunity.  To determine if this was the case, we generated oligoclonal Epstein 181	
Barr Virus (EBV)-specific cytotoxic T-cell lines from normal donors, as previously 182	
described19. These cells lysed autologous EBV-transformed cells (Figure 2c).  Staining 183	
in 3 donors revealed the cells were >98% CD8+ (data not shown) and contained a 184	
mixed population of TRBC1+ and TRBC1- (median 45% TRBC1+) cells, 185	
demonstrating that the T-cell response to EBV contains both populations (Figure 2d).  186	
In addition, we identified T-cells specific for cytomegalovirus (CMV) or adenovirus 187	
(AdV) by incubation of peripheral blood mononuclear cells (PBMCs) with pools of 188	
antigenic peptides. Viral-specific T-cells, identified by interferon-gamma (IFN-g) 189	
expression after peptide incubation (Figure 2e), were found to contain both TRBC1+ 190	
and TRBC1- cells (Figure 2f). Summary data from normal donors demonstrated 191	
median TRBC1 expression of 45% (CMV) and 41% (AdV) (Figure 2g). 192	
 193	
 194	
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T-cell derived malignant cell lines and primary T-cell tumours are clonally 195	
TRBC1+ or TRBC1- 196	
 197	
Surface TCR+ cell lines were stained with JOVI-1 and were found to be either TRBC1+ 198	
(H9, Jurkat, MJ) or TRBC1- (HD-Mar2, HPB-ALL, T-ALL1, HH, T-ALL1). TRBC1 199	
versus TRBC2 expression was confirmed at the transcriptional level by PCR 200	
amplification of the β-constant region from cDNA, followed by Sanger sequencing 201	
(Figure 3a). These data confirmed JOVI-1 as a marker of TRBC1 clonality in cell lines. 202	
Next, using multiparameter flow cytometry, we analysed primary blood samples from 203	
several patients with T-large granular leukaemia (T-LGL), a TCR+ lymphoproliferative 204	
disorder characterised by circulating tumour cells which express CD5720.  While 205	
CD57+ tumour cells demonstrated markedly skewed TRBC1:TRBC2 ratios, normal 206	
CD4+ and CD8+ T-cells displayed appropriate ratios of each population (Figure 3b). 207	
Using intracellular staining, we replicated this finding in primary marrow samples of T-208	
ALL (Figure 3c). Further, using flow cytometry (FACS) or immunohistochemistry (IHC) 209	
on frozen tissue sections, we stained a number of primary samples of TCR+ 210	
malignancies of multiple histologies and confirmed that TRBC1 staining could be used 211	
to determine if tumours were clonally TRBC1+ or TRBC1- (Figure 3d,e). In 58 samples 212	
(38 analysed by IHC, 20 by FACS), 40% were TRBC1+ and 60% were TRBC1- (Figure 213	
3f). Of note, TCR/CD3 expression assayed by FACS in primary tumours was typically 214	
at a similar level to admixed normal T-cells (median MFI = 96% of normal T-cell MFI), 215	
other than in adult T-cell leukaemia/ lymphoma (ATLL) where expression was typically 216	
dimmer than in normal T-cells (median MFI 23% of normal T-cell MFI, Fig 3g). 217	
 218	
T-cells transduced with anti-TRBC1 CAR specifically target TRBC1+ but not 219	
TRBC2+ cells in vitro 220	
 221	
As a proof of concept for therapies targeting TRBC we cloned a single-chain variable 222	
fragment based on the JOVI-1 antibody into a 3rd generation CAR format21. We 223	
retrovirally transduced T-cells from normal donors to stably express this construct, and 224	
confirmed surface expression of CAR on up to 90% of cells (Fig 4a).  We subsequently 225	
co-cultured non-transduced (NT) or anti-TRBC1 CAR T-cells with NT-JKO, TRBC1-226	
JKO or TRBC2-JKO cells. While NT effectors did not secrete IFN-g in response to any 227	
target cells, TRBC1 CAR T-cells specifically released IFN-g only when incubated with 228	
TRBC1-JKO and not NT-JKO or TRBC2-JKO cells (Figure 4b,c). In 4hr chromium 229	
release cytotoxicity assays, NT cells did not display cytotoxicity, while anti-TRBC1 230	
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CAR T-cells specifically killed TRBC1-JKO and not NT-JKO or TRBC2-JKO cells 231	
(Figure 4d,e).  232	
 233	
In addition, we performed flow cytometric cytotoxicity assays using multiple α/ β TCR+ 234	
cell lines as targets, and confirmed killing of TRBC1+ but not TRBC2+ cell lines by 235	
anti-TRBC1 CAR T-cells, while NT T-cells did not lyse either (Figure 4f). Next, to 236	
simulate a physiological setting, we mixed TRBC1-JKO cells labelled with CD19 237	
marker gene at 1:1 ratio with TRBC2-JKO cells labelled with blue fluorescent protein 238	
(BFP). This population was co-cultured with anti-TRBC1 CAR-T or NT cells. Analysis 239	
at 48hrs confirmed eradication of TRBC1 cells with preservation of TRBC2 cells by 240	
anti-TRBC1 CAR, and no killing of either population seen with NT effectors (Figure 241	
4g).   242	
 243	
We obtained primary tumour cells from multiple patients with TRBC1+ T-cell 244	
malignancies.  We co-cultured patient tumour with NT or anti-TRBC1 CART-cells at a 245	
1:1 ratio. Using allogeneic T-cells, we demonstrated specific kill of tumour in cases of 246	
T-prolymphocytic leukaemia (T-PLL) and PTCL-NOS, with preservation of a 247	
substantial proportion of residual normal T-cells (Figure 4h). Tumour kill was seen 248	
even in cases of ATLL (Figure 4i,l), where TCR/CD3 was partially downregulated from 249	
the cell surface (Figure 2g). In addition, we demonstrated successful transduction of 250	
T-cells from a patient with TRBC1+ malignancy (ATLL) despite heavy circulating 251	
tumour burden (Figure 4j), that the T-cell product was ‘purged’ of contaminating tumour 252	
cells (Figure 4k) and that anti-TRBC1 CAR specifically killed autologous tumour cells 253	
(Figure 4l). 254	
 255	
Anti-TRBC1 CAR-T cells selectively deplete normal TRBC1, but not TRBC2 cells 256	
 257	
Following anti-TRBC1 CAR transduction, no TRBC1+ cells could be detected in either 258	
the transduced or non-transduced fractions, indicating possible depletion of this 259	
population (Suppl Fig 3a). However, we reasoned that absent TRBC1 staining was 260	
likely due to epitope blocking by ligated anti-TRBC1 CAR. Therefore, we transduced 261	
cells with anti-TRBC1 CAR and CD34 marker gene22. This enabled sorting of cells into 262	
CAR+ and CAR- fractions using CD34-bead magnetic depletion. We confirmed 263	
depletion of all CAR+ cells in the –ve fraction, thus excluding any effect of epitope 264	
blockade by CAR.  While NT cells contained both TRBC1+ and TRBC1- fractions, the 265	
CAR –ve fraction did not contain any TRBC1+ cells, confirming selective depletion of 266	
TRBC1 cells (Suppl Figure 3b). Further, we sorted normal donor T-cells into TRBC1+ 267	
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and TRBC1- populations using magnetic beads. We subsequently separately labelled 268	
each population with different fluorescent nuclear dyes, enabling later discrimination 269	
of the populations, and co-cultured with autologous NT or anti-TRBC1 CART-cells. 270	
While TRBC2 cells co-cultured with anti-TRBC1 CAR were not depleted compared to 271	
NT condition, TRBC1 cells were 80% depleted at 7 days (Suppl Figure 3c), indicating 272	
selective purging of this population.  This was confirmed in a further assay, in which 273	
TRBC1 cells were mixed at a 1:2 (physiological) ratio with TRBC2 cells before 1:1 co-274	
culture with NT or anti-TRBC1 cells. At 7 days, virtually all TRBC1 cells had been 275	
depleted from the culture, while TRBC2 cells remained (Suppl Fig 3d). Finally, to 276	
further mitigate against potential transduction of contaminating TRBC1 tumour cells, 277	
we pre-depleted normal donor T-cells of TRBC1+ cells to obtain cells which were >99% 278	
TRBC1- (Supplementary Figure 3e), then demonstrated transduction with anti-TRBC1 279	
CAR that was similar to that achieved for unsorted cells (Supplementary Figure 3f). 280	
 281	
 282	
Anti-TRBC1 CAR-T cells specifically killed TRBC1+ tumour while preserving 283	
TRBC2+ tumour in murine models of disseminated T-cell malignancy. 284	
 285	
We utilised an established murine xenograft model of disseminated T-cell leukaemia. 286	
Non-obese diabetic-severe combined immunodeficiency g-chain–deficient (NSG) mice 287	
(Jackson) were intravenously injected with Jurkat T-cells, which natively express a 288	
TRBC1 TCR at a level similar to primary tumour and normal T-cells (Figure 2g). Jurkat 289	
cells were modified to stably express firefly luciferase (F-Luc) and CD19 marker gene, 290	
and stably engrafted in the bone marrow of all injected animals by day 6 (Figure 5a,b). 291	
Following engraftment, we treated mice with T-cells expressing anti-TRBC1 CAR or a 292	
control (irrelevant) CAR. Mice treated with anti-TRBC1 CAR had dramatic tumour 293	
reduction by BLI at D10 (Figure 5b,c), and this was associated with a substantial 294	
survival benefit. In a further experiment to evaluate CAR persistence (Figure 5e), we 295	
demonstrated tumour clearance and increased numbers of anti-TRBC1 versus control 296	
CAR T-cells in peripheral blood at D21 following T-cell injection (Figure 5f). Bone 297	
marrow was harvested at the time of death (survivors culled at D42), with similar results 298	
seen (Figure 5g).   299	
 300	
Next, we injected a further cohort of mice with equal proportions of Jurkat-TRBC1 cells 301	
(human CD19 marker gene) and JKO cells engineered to express TRBC2 TCR and 302	
BFP marker gene). Tumour engraftment in marrow was confirmed in all animals by BLI 303	
at day 6. Animals were then treated with NT or anti-TRBC1 CAR T-cells. Flow 304	
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cytometry of bone marrow confirmed the TRBC1 specificity of anti-TRBC1 CAR T-cells 305	
in vivo: while mice receiving NT effectors had approximately equal proportions of 306	
Jurkat-TRBC1 and JKO-TRBC2 cells in marrow, only JKO-TRBC2 cells were seen in 307	
recipients of anti-TRBC1 CAR T-cells (Figure 5e,f).  308	
 309	
Finally, in order to determine if anti-TRBC1 CAR was able to deplete TRBC1 tumour 310	
in a physiological setting (ie in the presence of normal T-cells), we engrafted NSG mice 311	
with Jurkat-CD19-Fluc tumour as before. After 7 days, mice were injected with human 312	
PBMCs (Supplementary Fig 4a). After a further 7 days, human monocyte and T-cell 313	
engraftment was confirmed by flow cytometry of peripheral blood (Supplementary Fig 314	
4b), and progressive disease was demonstrated by BLI (Supplementary Fig 4c). 315	
Animals were then injected with anti-TRBC1 CAR or control CAR, with cells prepared 316	
from the same donor as initial PBMCs.  BLI and flow cytometry of bone marrow at 5 317	
days following treatment demonstrated tumour control in anti-TRBC1 CAR recipients, 318	
but disease progression in control CAR recipients (Supplementary Fig 4c,d,e). Flow 319	
cytometry of bone marrow (Supplementary Figure 4e) and spleen (Supplementary 320	
Figure 4f) at D6 demonstrated similar numbers of non-CAR T-cells were present in 321	
anti-TRBC1 and control CAR recipients, confirming persistence of normal T-cells in 322	
the face of tumour depletion. 323	
 324	
 325	
 326	
  327	
Maciocia	et	al	 Targeting	differences	in	TCR-Β	 Page	12	of	35	
	
	 12	
DISCUSSION 328	
 329	
The presence of two functionally identical genes at the TCR-β constant region has 330	
been recognised for more than 30 years14,15, but has not been exploited until now. We 331	
have demonstrated that despite highly similar amino acid sequences, it is possible to 332	
discriminate between TRBC1 and TRBC2 proteins on normal and malignant T-cells. 333	
Indeed, JOVI-1 demonstrated >10,000-fold difference in binding affinity, with specificity 334	
based on the reversal of only 2 residues in TRBC. Consistent with previous findings, 335	
we have shown that approximately 2/3 of both normal T-cells23,24 and T-cell cancers25 336	
express TRBC2-TCR. 337	
 338	
We believe TRBC1/2 targeting has considerable potential for immunotherapy of T-cell 339	
malignancies. The principle of using immunotherapy to target a rearranged clone-340	
specific receptor is not new: Stevenson et al pioneered the use of patient-specific anti-341	
idiotype mAbs against neoplastic lymphoma cells26,27. However, this approach is 342	
impracticable since it requires a novel binder to be generated for each patient. An 343	
analogous approach to ours,  targeting B-cell cancers with antibody light-chain specific 344	
therapy has also been proposed28.  345	
 346	
Patients with B-cell malignancies have greatly benefited from the advent of potent 347	
immunotherapies. Rituximab, usually given in combination with cytotoxic 348	
chemotherapy, has dramatically improved outcomes in indolent29 and aggressive B-349	
cell lymphomas30 and is now part of standard front-line therapy. Further agents 350	
including depleting antibodies, radio-immune conjugates, bi-specific T-cell engagers 351	
and other modalities have also proven effective and are in widespread use31.  Of 352	
immunotherapies in development, perhaps the most promising approach is CAR T-353	
cells. Treatment of B-cell malignancies with anti-CD19 CART-cells has been one of 354	
the most important recent advances in the treatment of cancer, with sustained 355	
remissions obtained in most patients with advanced and refractory B-ALL6,32, as well 356	
as impressive though lesser responses in CLL7,33 and diffuse large B-cell lymphoma7. 357	
Given the relatively similar presentation and nature of B- and T-cell malignancies, 358	
CART-cells could potentially have similar value in treating T-cell lymphomas.  359	
 360	
However, anti-CD19 CART efficacy is accompanied by loss of the normal B-cell 361	
compartment6,7. While this is relatively well tolerated, and impact can be lessened by 362	
infusion of donor–derived pooled immunoglobulins, analogously targeting a pan-T-cell 363	
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antigen on a T-cell malignancy (with concomitant permanent loss of normal T-cells) 364	
would be prohibitively toxic, with no mitigating replacement therapies available.  365	
 366	
Approaches using CARs against T-cell targets such as the pan T-cell antigen CD534 367	
or CD4, which is present on a crucial subset of normal T-cells35, have been proposed, 368	
but may prove unacceptably immunosuppressive in clinical use. With our approach, a 369	
patient treated with anti-TRBC1 CART would retain approximately 2/3 of normal T-370	
cells, with polyclonal anti-viral immunity likely preserved. In addition, the potential for 371	
‘on-target off-tumour’ toxicity affecting other tissues would be negligible, given the 372	
restriction of TCR expression to mature T- or NK/T-cells.  However, with any approach 373	
targeting T-cells rather than B-cells increased cytokine-mediated toxicity could occur, 374	
due to lysis of normal tissue-resident T-cells and subsequent mediator release. 375	
Another potential consequence of depletion of part of the regulatory T-cell repertoire 376	
could be loss of some peripheral tolerance, if the T-regulatory cells protecting a 377	
particular tissue were particularly skewed towards TRBC1 or 2. However, ultimately 378	
the toxicities associated with depletion of TRBC1 or 2 cells could only be examined in 379	
a clinical trial.   380	
 381	
In summary, we have demonstrated a novel approach to investigation and targeting of 382	
T-cell malignancies by distinguishing between two possible TCR beta-chain constant 383	
regions. Using CART-cells targeting one constant region we have demonstrated proof 384	
of concept. Exploration of the distribution of constant region usage by unselected 385	
normal T-cells and those providing specific viral immunity suggests that such an 386	
approach would not lead to significant immunosuppression. We hope that this 387	
approach heralds the application of potent targeted immunotherapeutics to provide 388	
much needed enhancement of the treatment of T-cell malignancies. 389	
 390	
 391	
  392	
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OUTLINE METHODS 508	
  509	
Cell lines 510	
 511	
293T and K562 cell lines were cultured in IMDM (Lonza, Basel, Switzerland) 512	
supplemented with 10% FBS (FBS, HyClone, GE, Buckinghamshire, UK) and 2 mM 513	
GlutaMax (Invitrogen, CA, USA). Jurkat, Jurkat TCR-KO (and engineered variants), 514	
HD-Mar2, HPB-ALL, H9, T-ALL1, MJ, CCRF-CEM and HH cells were cultured in 515	
complete RPMI (RPMI1640, Lonza, Basel, Switzerland, supplemented with 10% FBS 516	
and 2 mM GlutaMax). Cells were maintained in a humidified atmosphere containing 517	
5% CO2 at 37°C. All cell lines were routinely tested for mycoplasma and for surface 518	
expression of target antigens. All cell lines were obtained from American Tissue 519	
Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und 520	
Zellkulturen (DSMZ) or Public Heath England collections. Jurkat TCR-KO cells were a 521	
kind gift from the laboratory of Prof Hans Stauss. 522	
 523	
 524	
Cloning, expression and purification of TCR protein. 525	
 526	
The C5861 TCR expressing a TRBC2 domain36 and the ILA1 TCR expressing a 527	
TRBC1 domain37, constructed using a disulphide-linked construct, were used to 528	
produce the soluble α- and β- chain domains (variable and constant) for each TCR. 529	
The TCRα and TCRβ chains were inserted into separate pGMT7 expression plasmids 530	
under the control of the T7 promoter. Competent Rosetta DE3 E. Coli cells (Merck, 531	
Darmstadt, Germany) were used to produce the C5861 and ILA1 TCRs in the form of 532	
inclusion bodies using 0.5M IPTG to induce expression. Soluble C5861 and ILA1 533	
TCRs were refolded as previously described36 purified by anion exchange (Poros 534	
50HQ, Life Technologies, Cheshire, UK) and size exclusion chromatography (S200 535	
GR, GE Healthcare, Buckinghamshire, U.K.). 536	
 537	
Surface Plasmon Resonance (SPR) analysis  538	
 539	
The binding analysis was performed using a Biacore T200 (GE Healthcare, 540	
Buckinghamshire, UK) equipped with a CM5 sensor chip as previously reported38. 541	
Briefly, 500-1000 Response Units (RUs) of JOVI-1 antibody was linked by amine 542	
coupling to the chip surface. For the C5861 TRBC2 TCR, ten serial dilutions were 543	
injected over the immobilised JOVI-1 and equibilibrium binding analysis was 544	
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performed. The equilibrium-binding constant (KD (E)) values were calculated using a 545	
nonlinear curve fit (y = (P1x)/(P2+x)). For the ILA1 TRBC1 TCR, single kinetic 546	
injections were performed. For kinetics analysis, the Kon and Koff values were 547	
calculated assuming 1:1 Langmuir binding and the data were analysed using a global 548	
fit algorithm (BIAevaluation 3.1™).  549	
 550	
Cell staining and flow cytometry 551	
 552	
Flow cytometry was performed using BD LSR Fortessa instrument (BD, NJ, USA). 553	
FACS sorting was performed using BD FACSAria (BD, NJ, USA).  Staining steps were 554	
performed at room temperature for 20 minutes, with PBS washes between steps. For 555	
staining of intracellular antigens cells were fixed and permeabilised with 100uL of 556	
Cytofix/ Cytoperm (BD, NJ, USA) for 5 minutes prior to staining, and wash steps were 557	
performed using PermWash (BD, NJ, USA). The following antibodies were used (all 558	
anti-human unless otherwise specified, clone identity in brackets): CD2 (TS1/8), CD3 559	
(UCHT1), CD4 (OKT4), CD5 (UCHT2), CD7 (CD7-6B7), CD8 (SK1), human/ murine 560	
CD11b (M1/70), CD14 (M5E2), CD19 (HIB19), CD25 (BC96), CD45 (HI30), CD45RA 561	
(HI100), CD56 (HCD56), CD57 (HCD57), CCR7 (GO43H7), TCR α/β (T10B9), all from 562	
Biolegend, San Diego, CA, USA; CD34 (Qbend10, Miltenyi, Bergisch Gladbach, 563	
Germany); TRBC1 (JOVI-1, Ansell, Bayport, MN, USA), fixable viability dye 564	
(eBioscience, ThermoFisher, Waltham, MA, USA). Anti-TRBC1 CAR expression was 565	
detected by staining for RQR8 marker gene22 with anti-CD34, or anti-MuFab  (115-566	
116-072, Jackson Immuno, Westgrove, PA, USA). All antibodies other than JOVI-1 567	
were validated by manufacturer for diagnostic use. At least 5000 target events were 568	
acquired per sample. Analyses were conducted using FlowJo v10 (Treestar, Ashland, 569	
OR, USA). 570	
 571	
 572	
Normal donors and viral peptide stimulation assays 573	
 574	
Approval for this study was obtained from the National Research Ethics Service, 575	
Research Ethics Committee 4 (REC Reference number 09/H0715/64). All normal 576	
donors provided informed consent.  577	
 578	
PBMCs from unselected heathy donors were isolated by Ficoll-Paque (GE Healthcare, 579	
Buckinghamshire, UK) gradient centrifugation were resuspended at 2 x 10^6 cells/ml 580	
in 1ml complete media in wells of a 24-well plate.  Overlapping peptide pools (15-mer, 581	
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11-mer overlap) derived from commonly immunogenic viral proteins were obtained 582	
from JPT Technologies (Berlin, Germany, USA). The viruses investigated (protein 583	
antigens in brackets) were cytomegalovirus, CMV (PP65) and adenovirus, AdV (hexon 584	
and penton). Peptide pools were supplied as dried pellets containing 25ug/peptide and 585	
were reconstituted in 50uL DMSO. To obtain a final concentration of 1ug/peptide/ml, 586	
2ul of each peptide pool was added to each well of PBMCs. 587	
 588	
After 1hr initial incubation, brefeldin A (BD, NJ, USA) was added to prevent Golgi 589	
transport. After a further 14hrs of culture, the cells were washed and surface staining 590	
was performed for viability, CD4 and CD8. The cells were then washed and lysed/ 591	
permeabilised, then stained for intracellular interferon-g, CD3 and JOVI-1 before 592	
resuspension for FACS analysis. Negative control peptide pool (actin, a ubiquitous 593	
cytoskeletal protein) and positive control (PMA/ ionomycin, Sigma Aldrich, Darmstadt, 594	
Germany) conditions were included. Low-frequency viral-specific T-cells were 595	
identified by intracellular interferon-gamma expression, with positive response 596	
threshold set as >0.01% above negative control staining.  597	
 598	
Identification of T-cell diiferentiation subsets and mucosal-associated invariate 599	
T-cells (MAITs) in normal donor peripheral blood 600	
 601	
Cells were defined as: naïve (CD45RA+CD45RO-CCR7-CD62L-), central memory 602	
(CD45RA-CD45RO+CCR7+CD62L+), effector memory (CD45RA-CD45RO+CCR7-603	
CD62L-) and effector (CD45RA-CD45RO+CCR7+CD62L+) and T-regulatory cells 604	
(CD4+FOXP3+CD25+). MAITs were identified as CD3+CD8+CD4-CD161+TCR-605	
Va7.2 +ve. 606	
 607	
Invariant Natural Killer T-cell (iNKT) isolation 608	
 609	
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor blood 610	
bags (Welsh Blood Service) using standard density gradient centrifugation. iNKT cells 611	
were purified from PBMC by magnetic separation using anti-iNKT TCR beads (Miltenyi 612	
Biotec) according to manufacturer’s recommendations. The purified cell fraction was 613	
subsequently expanded with phytohaemagglutinin and allogeneic irradiated feeders 614	
from three donors. After a minimum of 14 days post expansion, cells were phenotyped 615	
and used in functional assays. 616	
 617	
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Molt-3 cell line (endogenously expressing CD1d) was pulsed overnight with 100 ng/ml 618	
α-galactosylceramide (αGalCer, Sigma). iNKT lines were subsequently co-incubated 619	
with Molt-3 pulsed with αGalCer for 5 hours in presence of monensin, brefeldin A and 620	
CD107a antibody (all from BD Biosciences), according to manufacturer’s 621	
recommendations. iNKT lines were also incubated with media only, and with Molt-3 622	
pulsed with vehicle only (DMSO). iNKTs were identified by upregulation of CD107a 623	
and IFN-g in response to Molt-3 pulsed with αGalCer. 624	
 625	
 626	
Retroviral transduction of T-cells 627	
 628	
RD114-pseudotyped supernatant was generated as follows: 293T cells were 629	
transfected with vector plasmid; RDF, an expression plasmid to supply RD114 630	
envelope (gift of Mary Collins, University College London); and PeqPam-env, a gagpol 631	
expression plasmid (gift of Elio Vanin, Baylor College of Medicine). Transfection was 632	
facilitated using Genejuice (Merck, Darmstad, Germany). Peripheral blood 633	
mononuclear cell transductions were performed as follows: T cells from normal donors 634	
were isolated by Ficoll (GE, Buckinghamshire, UK) gradient centrifugation and 635	
stimulated with phytohemagglutinin (Sigma Aldrich, Darmstadt, Germany) at 5mg/mL. 636	
Interleukin-2 (IL-2, Genscript, Nanjing, China) stimulation (100 IU/mL) was added 637	
following overnight stimulation. On day 3, T cells were harvested, plated on retronectin 638	
(Takara, Nojihigashi, Japan) and retroviral supernatant, and centrifuged at 1000g for 639	
40 minutes. Transduction efficiency was determined on D6-7 following initial harvest 640	
and further experiments were commenced on D7-10 following initial harvest. PBMCs 641	
were maintained in complete RPMI. 642	
 643	
Generation and cytotoxicity assessment of EBV-specific CTLs 644	
 645	
This was performed as previously described19. Briefly, PBMCs from a normal donor 646	
were infected with EBV resulting in B-cell transformation to produce immortalised 647	
lymphoblastoid cells. These cells were irradiated and used as target cells to stimulate 648	
untransfomed PBMCs from the same donor, selectively expanding EBV-specific CTLs 649	
over a 23-day period. Cytotoxicity of EBV-CTLs against K562 cell line (an 650	
erythroleukaemia cell line with loss of MHC class 1 expression), allogeneic and 651	
autologous lymphoblastoid cells was assessed using standard 4hr chromium release 652	
cytotoxicity assays as previously described39. 653	
 654	
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 655	
Preparation and staining of primary tumour samples for FACS or 656	
immunohistochemistry 657	
 658	
Approval for this study was obtained from the National Research Ethics Service, 659	
Research Ethics Committee 4 (REC Reference number 09/H0715/64). Informed 660	
consent was obtained from all patients. For FACS, PBMCs from patients with T-cell 661	
malignancies were obtained from whole blood or marrow samples by Ficoll-Paque (GE 662	
Healthcare, Buckinghamshire, UK) gradient centrifugation prior to staining and 663	
analysis as above. Gating strategies to identify tumour and healthy T-cells were 664	
determined on a patient-specific basis according to data previously obtained by 665	
primary clinical laboratories.  For immunohistochemistry, fresh biopsy samples of 666	
patients with a range of T-cell malignancies (see Figure 3f) were snap-frozen in liquid 667	
nitrogen and tissue sections were prepared according to standard methodology. The 668	
investigated antibodies included the mouse monoclonal anti-T Cell Receptor Beta 1 669	
(clone JOVI.1; Ancell Corporation, Bayport, MN, USA) and the mouse monoclonal anti-670	
TCR beta F1 (clone 8A3; Thermo Fisher Scientific, Loughborough, UK). The 671	
antibodies were assessed under different conditions (i.e. dilution and antigen retrieval 672	
protocol) and the chosen dilution which showed selective background-free reaction in 673	
fresh tissue sections of human reactive tonsils (nr. 2) used as positive control were 674	
1:5000 for JOVI.1 and 1:50 for TCR Beta F1 respectively. The staining procedure was 675	
performed using the Roche-Ventana BenchMark Ultra autostainer (Ventana Medical 676	
System, Tuscon, US). Counterstaining was performed using haematoxylin and bluing 677	
reagent from Ventana/Roche; slides were mounted with cover slips and air-dried. 678	
 679	
 680	
Chromium release cytotoxicity assays 681	
 682	
Standard 4hr chromium release cytotoxicity assays were performed as previously 683	
described39, with all assays performed in triplicate. NK cell depletion was performed 684	
prior to assays using CD56 magnetic bead depletion and LD columns (Miltenyi, 685	
Begisch Gladbach, Germany). 686	
 687	
FACS-based co-culture and cytotoxicity assays 688	
 689	
Target and effector cells were resuspended at 1M cells/ml in complete media. 50-690	
100uL of each cell suspension was added to wells of a V-bottom 96-well plate to 691	
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achieve a 1:1 E:T ratio with 50 000 or 100 000 targets/ well.  For some experiments 692	
target cell were pre-labelled with carboxyfluorescein succinimidyl ester (CFSE) or 693	
CellTrace Violet (CTV, both Invitrogen, Carlsbad, CA, USA) dyes according to 694	
manufacturer’s instructions. The plate was placed in a standard cell culture incubator 695	
containing 5% CO2 at 37°C. After 24hrs the plate was spun down at 400G for 5mins, 696	
100uL of supernatant was removed for cytokine assays and replaced with fresh 697	
complete media. At 48hrs or 7 days, the plate was spun down at 400G for 5mins and 698	
supernatant was decanted. 100uL of staining cocktail (appropriate antibodies/ viability 699	
dye (eBioscience, ThermoFisher, Waltham, MA, USA) diluted in PBS) was added and 700	
cells were stained for 20mins in the dark at room temperature.  Wells were then 701	
washed with a further 100uL of PBS and spun down at 400G for 5 mins. Supernatant 702	
was decanted. Counting beads (Flow check fluorospheres, BD, NJ, USA) were 703	
washed in PBS then resuspended at 100 000 beads/ ml in PBS. 100uL of PBS/ 704	
counting bead mixture was added to each cells (10 000 beads/ well). 2000 beads were 705	
acquired per sample. Gating on single live target cells was performed according to 706	
exclusion of fixable viability dye, forward and side scatter characteristics and 707	
expression of fluorescent protein, marker gene or fluorescent dye. Assays were 708	
performed in triplicate. % cytotoxicity was calculated as: 10000/ number of beads 709	
collected x number of target cells at end/ number of target cells at start of culture x 710	
100. 711	
 712	
For primary tumour killing experiments, allogeneic or autologous T-cells were used, 713	
depending on the availability of cryopreserved normal patient T-cells. Bespoke gating 714	
strategies were used to identify normal and malignant T-cells in each patient sample. 715	
 716	
Cell sorting with magnetic bead selection 717	
 718	
Transduced T-cells positive or negative for the RQR8 marker gene (contains 719	
Qbend10-CD34 epitope) were selected by positive or negative bead selection 720	
according to the manufacturer’ instructions (Miltenyi, Miltenyi, Bergisch Gladbach, 721	
Germany) using MS or LD columns respectively. For TRBC1 T-cell positive or negative 722	
selection, cells were initially stained with JOVI-1-biotin then incubated with 723	
streptavidin-conjugated magnetic beads, then separated according to the 724	
manufacturer’s instructions. To increase purity a second selection/ depletion round 725	
was performed. 726	
 727	
Murine models of T-cell malignancy 728	
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 729	
This work was performed under United Kingdom home-office–approved project license 730	
and was approved by University College London Biological Services Ethical Review 731	
Committee. 6-8 week old male non-obese diabetic-severe combined 732	
immunodeficiency g-chain–deficient (NSG) mice (Jackson Laboratory, Bar Harbor, 733	
ME, USA) were intravenously injected via the tail vein with tumour cells, human 734	
PBMCs or CAR T-cells as described in the text. An otherwise identical irrelevant 735	
control CAR targeting B-cell maturation antigen, which is not expressed in T-cell 736	
malignancies, was used in some experiments as indicated in the text. Tail vein bleeds 737	
of 50uL were undertaken as indicated in the text. At the time of cull, in some 738	
experiments bone marrow was harvested. Single cell suspensions were prepared and 739	
analysed for presence of T-cells and residual tumour by flow cytometry. Tumour cells 740	
were identified by CD19 or BFP marker gene according to experiment. CAR T-cells 741	
were identified by expression of RQR8 marker gene. 742	
 743	
For experiments with a survival endpoint or engraftment of PBMCs, mice were 744	
monitored with at least twice weekly weighing. Animals with >10% weight loss or those 745	
displaying evidence of GvHD or tumour progression including hunched posture, poor 746	
coat condition, reduced mobility, pilorection or hind limb paralysis were culled. 747	
 748	
Bioluminescent imaging of mice was performed using IVIS system (Perkin Elmer, 749	
Buckinghamshire, UK). Prior to imaging, animals were placed in an anesthetic 750	
chamber. General anesthesia was induced using inhaled isoflurane. Following 751	
induction, intraperitoneal injection of luciferin (200uL via 27G needle) was undertaken. 752	
After 2 minutes, mice were placed in the imaging chamber. Simultaneous optical and 753	
bioluminescent imaging was performed. Anaesthesia was maintained by continued 754	
inhalation of isoflurane during imaging.   755	
 756	
Statistical analyses 757	
 758	
Unless otherwise noted, data are summarised as mean ± SEM. Student’s t-test was 759	
used to determine statistically significant differences between samples for normally 760	
distributed variables, with Mann-Whitney U-test used for non-parametrically distributed 761	
variables. p < 0.05 (2-tailed) indicated a significant difference. Unless otherwise stated, 762	
variances were similar between study populations. When variances were unequal, 763	
Welch’s correction for unequal variance was used. Paired analyses were used when 764	
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appropriate. When 3 groups were compared, 1-way ANOVA with Dunnett’s test for 765	
multiple comparisons with alpha of 0.05 were used. When multiple t-tests were 766	
performed, statistical significance was determined using the Holm-Sidak method with 767	
alpha of 0.05. Neither randomisation nor blinding was done during the in vivo study. 768	
However, mice were matched based on the tumor signal for control and treatment 769	
groups before infusion of control or gene-modified T-cells. Cohort sizes were based 770	
on number required to demonstrate 90% reduction in tumour bioluminescence, 95% 771	
confidence with 80% power. Survival curves were generated using the Kaplan-Meier 772	
method with hazard ratios calculated by Mantel-Haenszel method. All animal studies 773	
were performed at least twice, with data presented representing one representative 774	
experiment. Graph generation and statistical analyses were performed using Prism 775	
version 7.0b software (GraphPad, La Jolla, CA, USA).  776	
 777	
 778	
 779	
 780	
 781	
 782	
 783	
 784	
 785	
 786	
 787	
 788	
 789	
 790	
 791	
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 792	
 793	
 794	
Figure 1: During T-cell receptor gene re-arrangement, each T-cell selects either 795	
TRBC1 or TRBC2, which can be specifically differentiated using an antibody. (a) 796	
Proposed structure of the TCR-CD3 complex assembled on T-cell surface (beta 797	
constant region highlighted) (b) The process of beta gene arrangement involving 798	
specific VDJ recombination (c) Alignment of TRBC1 and TRBC2 protein sequences, 799	
differences highlighted in red (d) Staining of non-transduced and engineered TRBC1-800	
JKO, TRBC2-JKO cell lines with CD3 and JOVI-1 antibodies (e) JOVI-1 staining of  801	
293T cells, transfected to express TCRs with varying specificities and TRBJ usage 802	
(gated on CD3+ cells) (f) JOVI-1 staining of engineered cell lines with each difference 803	
between TRBC1 and TRBC2 introduced individually (g) 3D representation of TRBC1 804	
and TRBC2 epitopes on the surface of TRBC. TCR = T-cell receptor; VDJ = variable, 805	
diversity, joining; JKO = Jurkat T-Cell receptor knockout. TRBC = T-cell receptor beta 806	
constant. 807	
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 814	
 815	
Figure 2: Unselected polyclonal and viral-specific T-cells contain both TRBC1+ and 816	
TRBC1- populations. (a) Staining of sample normal donor CD4 (left) and CD8 (right) 817	
T-cells with pan-TCR and JOVI-1 antibodies (b) Proportion of normal T-cells 818	
expressing TRBC1 in CD4 and CD8 compartments, data from 27 normal donors. (c) 819	
Killing of cell lines by EBV-CTLs, measured by 4hr chromium release assay (d) 820	
TRBC1+/TRBC1- proportion of EBV-CTLs in 3 normal donors (e) Identification of CMV 821	
or AdV-specific T-cells by IFN-G staining after peptide stimulation, data from 822	
representative donor (f) Staining of viral specific T-cells with CD3 and JOVI-1 (gated 823	
on cells as identified in e) (g) TRBC1 expression in viral specific cells, summary data 824	
from 3 (CMV) and 5 (AdV) normal donors. TCR = T-cell receptor, EBV = Epstein Barr 825	
virus, CTL = cytotoxic T-lymphocyte, CMV = cytomegalovirus, AdV = adenovirus, IFN-826	
G = interferon gamma. 827	
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 836	
 837	
Figure 3: T-cell-derived cell lines and primary T-cell malignancies are clonally 838	
TRBC1+ or TRBC1-. (a) Staining of cell lines with JOVI-1 (left panel), gated on CD3+ 839	
cells with matched Sanger sequencing traces of TCR-beta constant region (right 840	
panel) (b) Staining of normal and malignant T-cells from 2 representative patients with 841	
T-LGL, assessed by flow cytometry. Top panel shows TRBC1+ tumour, bottom panel 842	
shows TRBC1- tumour. Tumour gating = TCR+CD4-CD8+CD57+ Small numbers of 843	
TRBC1- cells in tope panel ‘tumour’ gate likely reflect normal CD8+CD57+ T-cells, 844	
clonality suggested by abnormal TRBC1+:TRBC1- ratio (c) Staining of normal and 845	
malignant T-cells from 2 representative patients with T-ALL, assessed by flow 846	
cytometry. Top panel shows TRBC1+ tumour, bottom panel shows TRBC1- tumour. 847	
Tumour gating = CD3(intra)+CD4+CD8+. (d) Staining of frozen tissue sections of 3 848	
cases of TCR+ TRBC1- lymphoma with TCR (left panel) and JOVI-1 (right panel). 849	
Positive cells stain brown. Small numbers of admixed polyclonal TRBC1+ T-cells are 850	
typically seen. Tumour histology: A = T-acute lymphoblastic leukaemia (T-ALL), B = 851	
angioimmunoblastic T-cell lymphoma (AITL), C = AITL (e) Staining of frozen tissue 852	
sections of 3 cases of TCR+ TRBC1+ lymphoma with TCR (left panel) and JOVI-1 853	
(right panel). Positive cells stain brown. A = anaplastic large cell lymphoma (ALCL), B 854	
= T-ALL, C = peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (f) 855	
Summary data of TRBC1 expression in primary samples of TCR+ malignancies. (g) 856	
TCR expression on tumour cells and TRBC1+ cell lines. Tumour expression of TCR 857	
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was quantified by MFI on FACS, and is expressed as a percentage of TCR expression 858	
on admixed normal T-cells from the same patient. Grey triangles represent cases of 859	
ATLL, with other histologies represented by black circles. Red triangle = Jurkat cell 860	
line. T-LGL = T-large granular lymphocytosis, T-ALL = T-acute lymphoblastic 861	
leukaemia, AITL = angioimmunoblastic lymphoma, ALCL = anaplastic large cell 862	
lymphoma, NK = natural killer, ATLL = adult T-cell leukaemia/ lymphoma, T-PLL = T-863	
prolymphocytic leukaemia. MFI = median fluorescence intensity. 864	
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 895	
 896	
Figure 4: Anti-TRBC1 CART-cells demonstrate efficacy and specificity against 897	
TRBC1+ tumours in vitro. (a) Example transduction shows anti-TRBC1 CAR 898	
expression on surface of transduced T-cells. (b) Interferon gamma release by NT or 899	
anti-TRBC1 CAR T-cells against TRBC1-JKO cells, 24-hour co-culture. (c) Interferon 900	
gamma release by anti-TRBC1 CAR T-cells against NT-JKO, TRBC1-JKO or TRBC2-901	
JKO cells, 24-hour co-culture. (d) Killing of TRBC1-JKO cells by NT or anti-TRBC1 902	
CART-cells, 4hr chromium release assay. *p<0.01 for comparison v NT effectors. (e) 903	
Killing of TRBC1-JKO or TRBC2-JKO cells by anti-TRBC1 CART-cells, 4hr chromium 904	
release assay *p<0.01 for comparison v JKO-NT target cells. (f) Flow-based 905	
cytotoxicity assay, target cell numbers expressed as % of starting cells after 48hrs. (g) 906	
Co-culture of mixed TRBC1/ TRBC2 cells, example FACS plot at 48hrs. (h) Primary T-907	
cell malignant samples with admixed normal CD8 T-cells after 120hr co-culture with 908	
NT or anti-TRBC1 allogeneic CAR –cells. Left panel = case of T-PLL, tumour cells 909	
were CD7bright CD4+. There were no normal CD4 cells but normal CD8 cells were 910	
present. Right panel = PTCL-NOS. Numbers represent % of events. Tumour cells were 911	
CD4brightCD7-. Normal admixed CD4 and CD8 cells were present. Numbers 912	
represent absolute numbers of events. (i) Primary ATLL sample after 72hr co-culture 913	
with allogeneic NT or anti-TRBC1 CAR T-cells. Tumour cells were CD3dimCD8+CD7-914	
. Numbers represent % of events. (j) Transduction of PBMCs from patient with ATLL, 915	
assessed by RQR8 marker gene. Grey = NT cells, black = anti-TRBC1. (k) Tumour 916	
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burden following transduction with anti-TRBC1 CAR. (l) Primary ATLL sample after 917	
72hr co-culture with autologous NT or anti-TRBC1 T-cells. Tumour gating = 918	
CD2+CD4+CD7-CD8-.  All experiments other than in j-l used effector T-cells from 919	
normal healthy donors. NT = non-transduced, JKO = Jurkat T-cell receptor-null, CAR 920	
= chimeric antigen receptor, BFP = blue fluorescent protein, ATLL = adult T-cell 921	
leukaemia/ lymphoma, T-PLL = T-prolymphocytic leukaemia, PTCL-NOS = peripheral 922	
T-cell lymphoma, not otherwise specified.  923	
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 954	
 955	
 956	
 957	
 958	
Figure 5: Efficacy and specificity of anti-TRBC1 CAR in murine models of TRBC1+ 959	
malignancy. (a) Flow diagram of Jurkat survival experiment (b) Bioluminescence 960	
imaging at D-1 and D10 following CAR injection (c) Radiance of individual animals at 961	
D10 following CAR injection, compared via Student’s t-test (d) Survival curve of 962	
animals in Jurkat experiment  (median OS 54 v 21 days, HR = 0.037, p < 0.00001, n 963	
= 10/ group) (e) Flow diagram of Jurkat persistence experiment (f) Jurkat tumour, total 964	
T-cell and CD8 CAR-T cell numbers from bleed at D21 following CAR injection (g) 965	
Numbers of total T-cells and CD8 CAR T-cells in marrow at time of cull (D42 in anti-966	
TRBC1 CAR recipients). Comparisons in f,g were made using Mann-Whitney U-test. 967	
CAR was detected by expression of RQR8 marker gene (h) Flow diagram of specificity 968	
experiment (i) Flow cytometry of bone marrow in NSG mice engrafted with equal 969	
proportions of TRBC1-Jurkat or TRBC2-JKO cells following treatment with NT 970	
effectors or anti-TRBC1 CART-cells, representative examples. TRBC1 cells were 971	
detected by CD19 marker gene, TRBC2 cells were detected by BFP marker gene) 972	
Quantification of TRBC1 proportion of residual Jurkat tumour by flow cytometry, 973	
individual values shown. All experiments used effector T-cells from normal healthy 974	
donors. Comparison by Student’s t-test. Horizontal lines represent median values. 975	
*
B
C
M
A
T
R
B
C
1
101
102
103
104
105
106
T
-c
e
ll
s
 (
n
)
*
B
C
M
A
T
R
B
C
1
0
2000
4000
6000
8000
10000
C
D
8
+
 C
A
R
 T
-C
e
ll
s
 (
n
)
B
C
M
A
T
R
B
C
1
100
101
102
103
104
T
-C
e
ll
s
 (
n
/u
L
)
*
! !NSG IV 3 x106 
Jurkat
-Fluc-CD19
IV 8 x105
CAR T
Cull
survivors
"
D-6 D0     2x/wk D21    D+42   
B
C
M
A
T
R
B
C
1
0
5
10
15
20
40
60
80
C
D
8
+
 C
A
R
T
-C
e
ll
s
 (
n
/u
L
)
**
B
C
M
A
T
R
B
C
1
0
50
100
150
200
250
T
u
m
o
u
r 
(n
/u
L
)
Marrow
0 20 40 60
0.0
0.5
1.0
Time from CAR Injection (Days)
F
ra
c
ti
o
n
 s
u
rv
iv
a
l
Bloode f g
a b d
B
C
M
A
T
R
B
C
1
104
106
108
1010
R
a
d
ia
n
c
e
 (
P
h
/s
/c
m
2
/s
r)
***
c
! !NSG IV 3 x106 
Jurkat
-Fluc-CD19
IV 8 x105
CAR T
Cull
survivors
D-6 D0     2x/wk D60
NT aTRBC1 CAR
TRBC1 (CD19)
T
R
B
C
2
 (
B
F
P
)
h j
NSG
IV 1.5 x106 each
Jurkat-CD19
JKO-TRBC2-BFP
IV 4 x106
CAR T-cells
Cull
D-6 D0 D+6
i
D10
D17
Anti-BCMA Anti-TRBC1
D-1 ***
***
N
T
C
A
R
0
20
40
60
80
100
T
R
B
C
1
+
 %
 o
f 
R
e
s
id
u
a
l 
T
u
m
o
u
r
Maciocia	et	al	 Targeting	differences	in	TCR-Β	 Page	32	of	35	
	
	 32	
*p<0.05, ***p<0.00001. BCMA = B-cell maturation antigen. BFP = blue fluorescent 976	
protein. 977	
 978	
 979	
 980	
 981	
Supplementary Figure 1: Surface plasmon resonance data of JOVI-1 binding to 982	
TRBC1 and TRBC2 TCR protein. JOVI-1 antibody (a) and single chain variable 983	
fragment (ScFv) (b) binding to C5861 (TRBC2) TCR protein. JOVI-1 antibody binding 984	
(c) and ScFv binding (d) to ILA1 (TRBC1) TCR. TCR = T-cell receptor, ScFv = single 985	
chain variable fragment. Top row = plots demonstrating TCR concentration v peak 986	
response units for binding to TRBC2 TCR, with time v response units plots at varying 987	
concentrations of TCR inset. Bottom row demonstrates time v response units plots for 988	
binding to TRBC1 TCR. 989	
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 998	
 999	
 1000	
 1001	
 1002	
 1003	
Supplementary Figure 2: TRBC1 expression in T-cell subsets. (a) Naïve 1004	
(CD45RA+CD45RO-CCR7-CD62L-), central memory (CD45RA-1005	
CD45RO+CCR7+CD62L+), effector memory (CD45RA-CD45RO+CCR7-CD62L-) 1006	
and effector (CD45RA-CD45RO+CCR7+CD62L+) were identified by FACS. Staining 1007	
with TCR and JOVI-1 antibodies demonstrated each T-cell population contained both 1008	
TRBC1+ and TRBC1- cells. Data from 1 donor shown, repeated in 4 donors. (b) iNKT 1009	
cell lines were produced as described in Methods section. Cells were 1010	
CD3+Valpha24Jalpha18+ (top row) and expressed TNF-alpha and CD107a in 1011	
response to Molt-3 cells pulsed with αGalCer (middle row, gated on iNKTs). Cells 1012	
expressed both TRBC1+ and TRBC1- TCRs (bottom row, gated on iNKTs). (c) MAITs 1013	
were identified as CD3+CD8+CD161brightValpha7.2 cells (left panel) and contained 1014	
both TRBC1 and TRBC2 cells (right panel) (d) Summary data of TRBC1 expression in 1015	
T-cell populations. TCR = T-cell receptor, MAIT = mucosal-associated invariant T-1016	
cells, iNKT = invariant natural killer/ T-cells. 1017	
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 1020	
 1021	
 1022	
 1023	
 1024	
 1025	
Supplementary Figure 3: Epitope blocking and primary T-cell cytotoxicity assay using 1026	
anti-TRBC1 CAR. a) NT cells (left) and anti-TRBC1 CAR-transduced cells (right) 1027	
stained with TCR and JOVI-1 antibodies, representative example, donor n > 10. b) 1028	
Anti-TRBC1 CAR T-cells sorted into CAR-ve and CAR +ve fractions by CD34 magnetic 1029	
sort, stained with anti-murine Fab antibody (left panel) or JOVI-1 antibody (right panel). 1030	
Representative example, repeated x 3 c) Killing of fluorescently labelled primary 1031	
TRBC1 or TRBC2 T-cells in 1:1 co-culture with autologous non-transduced or anti-1032	
TRBC1 CART-cells, FACS at 7 days, n = 3, ***p<0.001, unpaired t-test anti-TRBC1 1033	
CAR v NT effectors. d) Co-culture with CFSE-labelled TRBC1 and CTV-labelled 1034	
TRBC2 cells, mixed at 1:2 ratio and incubated with autologous NT or anti-TRBC1 CAR 1035	
T-cells, flow cytoemetry at 7 days, 1 representative donor shown, donor n = 3.  e) 1036	
Example of purity of TRBC1-depleted T-cells f) Transduction of unsorted or TRBC1-1037	
depleted T-cells with anti-TRBC1 CAR, transduction assessed by blue fluorescent 1038	
protein marker gene. 1 representative donor shown, repeated in >3 donors. All 1039	
experiments used T-cells from normal healthy donors. NT = non-transduced, CAR = 1040	
chimeric antigen receptor, CFSE = carboxyfluorescein, CTV = Cell Trace Violet 1041	
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 1042	
 1043	
 1044	
 1045	
 1046	
Supplementary Figure 4: Efficacy of anti-TRBC1 CAR against TRBC1+ Jurkat 1047	
tumour in human PBMC-engrafted mouse model. (a) Flow diagram of experiment (b) 1048	
Engraftment of human peripheral blood cells at D6 following PBMC injection (c) 1049	
Bioluminescence imaging of Jurkat tumour at D0 and D+6 following CAR injection 1050	
(85% CAR+) (d) Quantification of residual Jurkat tumour by bioluminescence imaging 1051	
(left) and flow cytometry of bone marrow (right). No Jurkat cells were present in spleens 1052	
of either group. (e) Quantification of normal non-Jurkat T-cells in marrow. (f) 1053	
Quantification of normal non-Jurkat T-cells in spleen. Anti-BCMA CAR-treated mice = 1054	
black, anti-TRBC1 CAR-treated mice = red. PBMCs and effector T-cells were derived 1055	
from the same healthy donor. Human monocytes were identified as CD45+CD3-CD19-1056	
CD11b+. Jurkat tumour cells were identified as CD45+CD3+CD19+CD4dim, normal 1057	
T-cells were identified as CD45+CD3+CD19-RQR8-CD4+CD8- or CD45+CD3+CD19-1058	
RQR8-CD4-CD8+, and CAR T-cells were identified as CD45+CD3+CD19-RQR8+. * p 1059	
< 0.05. Horizontal lines represent median values. All statistical comparisons used 1060	
Mann-Whitney U-test. PBMC = peripheral blood mononuclear cells, CAR = chimeric 1061	
antigen receptor, BCMA = B-cell maturation antigen. NS = non-significant 1062	
 1063	
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